UBS analyst Ashwani Verma raised the firm’s price target on Immunovant (IMVT) to $18 from $17 and keeps a Neutral rating on the shares. UBS remains cautious on the Immunovant story due to limited/no catalyst until 2027, as well as a financing overhang, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant 3M share Block Trade priced at $17.85
- Immunovant 3M share Block Trade; price range $17.85-$18.00
- Immunovant resumed with a Neutral at Goldman Sachs
- Immunovant’s IMVT-1402: A Promising Solution for Unmet Needs in Graves’ Disease
- 3 Best Stocks to Buy Now, 6/2/2025, According to Top Analysts